{"id":"fk949e","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Liver enzyme elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FK949E selectively activates androgen receptors in muscle and bone tissue, promoting anabolism and muscle growth with reduced activity in prostate and other androgenic tissues. This tissue-selective mechanism aims to provide the therapeutic benefits of androgens for conditions like muscle wasting and osteoporosis while avoiding unwanted androgenic effects associated with traditional androgens.","oneSentence":"FK949E is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:46:46.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Muscle wasting / sarcopenia"},{"name":"Osteoporosis"}]},"trialDetails":[{"nctId":"NCT01737268","phase":"PHASE3","title":"Long-term Study of FK949E in Elderly Bipolar Disorder Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-10-29","conditions":"Bipolar Disorder, Elderly","enrollment":20},{"nctId":"NCT01725308","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-02-07","conditions":"Bipolar Disorder","enrollment":431},{"nctId":"NCT02362412","phase":"PHASE3","title":"Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2015-02-18","conditions":"Bipolar Depression","enrollment":22},{"nctId":"NCT01725282","phase":"PHASE2","title":"Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-12-14","conditions":"Major Depressive Disorder","enrollment":172},{"nctId":"NCT01919008","phase":"PHASE1","title":"Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-03-26","conditions":"Major Depressive Disorder","enrollment":16},{"nctId":"NCT01871987","phase":"PHASE1","title":"Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Healthy, Plasma Concentration Change of Quetiapine","enrollment":24},{"nctId":"NCT01903200","phase":"PHASE1","title":"Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-02","conditions":"Major Depressive Disorder Patients","enrollment":16},{"nctId":"NCT01924520","phase":"PHASE1","title":"Oral Multiple-dose Study in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-11","conditions":"Major Depressive Disorder","enrollment":32},{"nctId":"NCT01908296","phase":"PHASE1","title":"Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-07","conditions":"Healthy, Pharmacokinetics of Quetiapine","enrollment":24},{"nctId":"NCT01871974","phase":"PHASE1","title":"Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Major Depressive Disorder Patients","enrollment":16}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HEPATITIS ACUTE"},{"count":1,"reaction":"MANIA"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["extended release formulation of quetiapine","extended-release formulation of quetiapine","quetiapine"],"phase":"phase_3","status":"active","brandName":"FK949E","genericName":"FK949E","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FK949E is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects. Used for Muscle wasting / sarcopenia, Osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}